Skip to main content
Erschienen in: Monatsschrift Kinderheilkunde 8/2009

01.08.2009 | Leitthema

Unterschiedliche Impfschemata in Europa

Führen alle Wege nach Rom?

verfasst von: Univ.-Prof. Dr. U. Wiedermann

Erschienen in: Monatsschrift Kinderheilkunde | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Verschiedene Impfschemata des Kinderimpfplans wurden hinsichtlich Wirksamkeit, Compliance und Kosteneffizienz verglichen. Für den 6-Fach-Impfstoff erwies sich ein reduziertes Schema (2 Grundimmunisierungen im 3. und 5. Lebensmonat, 1 Boosterimmunisierung mit 12 Monaten) als vergleichbar gut wie 3 Grundimmunisierungen im 1. und eine Auffrischungsimpfung im 2. Lebensjahr. Als Pneumokokkenimpfstoff im Kinderimpfplan steht derzeit ein 7-valenter Konjugatimpfstoff zur Verfügung, für welchen ebenfalls ein 2+1-Schema alternativ zum 3+1-Schema empfohlen werden kann. Eine Meningokokkenimpfung mit konjugierten Impfstoffen, die die Serogruppe C enthalten, ist für den Kinderimpfplan ebenso vorgesehen. Für Österreich wurden in Abhängigkeit vom Applikationsalter 3 Impfschemata ausgearbeitet, optimal sind eine Primärimpfung im 2. Lebensjahr und eine Auffrischungsimpfung im Vorschul- bzw. Adoleszentenalter. Ein Impfstoff gegen die am häufigsten vorkommende Serogruppe B steht momentan noch nicht zur Verfügung. Laut derzeitiger Literaturdaten sind die Impfempfehlungen für die genannten Impfstoffe mit reduzierten Impfschemata effizient und hinsichtlich Impfcompliance und Kostenüberlegungen empfehlenswert.
Literatur
1.
Zurück zum Zitat Aguiar SI, Serrano I, Pinto FR et al (2008) Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 14:835–843PubMedCrossRef Aguiar SI, Serrano I, Pinto FR et al (2008) Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 14:835–843PubMedCrossRef
2.
Zurück zum Zitat Borrow R, Goldblatt D, Finn A et al (2003) Immunogenicity of and immunologic memory to a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 71:5549–5555PubMedCrossRef Borrow R, Goldblatt D, Finn A et al (2003) Immunogenicity of and immunologic memory to a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 71:5549–5555PubMedCrossRef
3.
4.
Zurück zum Zitat Diggle MA, Clarke SC (2005) Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43:4649–4653PubMedCrossRef Diggle MA, Clarke SC (2005) Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43:4649–4653PubMedCrossRef
5.
Zurück zum Zitat European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561–565CrossRef European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561–565CrossRef
6.
Zurück zum Zitat Giambi C, Bella A, Barale A et al (2008) A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 8:100PubMedCrossRef Giambi C, Bella A, Barale A et al (2008) A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 8:100PubMedCrossRef
7.
Zurück zum Zitat Goldblatt D, Southern J, Ashton L et al (2006) Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25:312–319PubMedCrossRef Goldblatt D, Southern J, Ashton L et al (2006) Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25:312–319PubMedCrossRef
8.
Zurück zum Zitat Hak E, Sanders EA, Verheij TJ et al (2008) Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 66:378–383PubMed Hak E, Sanders EA, Verheij TJ et al (2008) Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 66:378–383PubMed
9.
Zurück zum Zitat Kayhty H, Peltola H, Karanko V, Makela PH (1983) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147:1100PubMed Kayhty H, Peltola H, Karanko V, Makela PH (1983) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147:1100PubMed
10.
Zurück zum Zitat Kilpi TM, Silfverdal SA, Nilsson L et al (2009) Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum Vaccin 5:18–25PubMed Kilpi TM, Silfverdal SA, Nilsson L et al (2009) Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age. Hum Vaccin 5:18–25PubMed
11.
Zurück zum Zitat Lackmann GM (2004) Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years. Med Sci Monit 10:PI96–PI98PubMed Lackmann GM (2004) Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years. Med Sci Monit 10:PI96–PI98PubMed
12.
Zurück zum Zitat Maiden MC, Ibarz-Pavon AB, Urwin R et al (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–743PubMedCrossRef Maiden MC, Ibarz-Pavon AB, Urwin R et al (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–743PubMedCrossRef
13.
Zurück zum Zitat Morsczeck C, Prokhorova T, Sigh J et al (2008) Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 14:74–81PubMedCrossRef Morsczeck C, Prokhorova T, Sigh J et al (2008) Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 14:74–81PubMedCrossRef
14.
Zurück zum Zitat Pichichero ME, Casey JR (2007) Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J 26:S12–S16PubMedCrossRef Pichichero ME, Casey JR (2007) Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J 26:S12–S16PubMedCrossRef
15.
Zurück zum Zitat Poolman J, Kaufhold A, De Grave D, Goldblatt D (2001) Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 19:2280–2285PubMedCrossRef Poolman J, Kaufhold A, De Grave D, Goldblatt D (2001) Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 19:2280–2285PubMedCrossRef
16.
Zurück zum Zitat Reinert P, Dejos V, Clyti N, Abitbol V (2008) Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar. Arch Pediatr 15:263–270PubMedCrossRef Reinert P, Dejos V, Clyti N, Abitbol V (2008) Immunogenicity and reactogenicity of DTPa-IPV-HBV/Hib and DTPa-IPV/Hib vaccines coadministered with 7-valent pneumococcal conjugate vaccine as primary vaccination and booster in healthy infants, according to the French vaccination calendar. Arch Pediatr 15:263–270PubMedCrossRef
17.
Zurück zum Zitat Schmitt HJ, Faber J, Lorenz I et al (2003) The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21:3653–3662PubMedCrossRef Schmitt HJ, Faber J, Lorenz I et al (2003) The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21:3653–3662PubMedCrossRef
18.
Zurück zum Zitat Schmitt HJ, Steul KS, Borkowski A et al (2008) Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine 26:2242–2252PubMedCrossRef Schmitt HJ, Steul KS, Borkowski A et al (2008) Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine 26:2242–2252PubMedCrossRef
19.
Zurück zum Zitat Scott D, Ruckle J, Dar M et al (2008) Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 50:295–299PubMedCrossRef Scott D, Ruckle J, Dar M et al (2008) Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 50:295–299PubMedCrossRef
20.
Zurück zum Zitat Snape MD, Kelly DF, Lewis S et al (2008) Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336:1487–1491PubMedCrossRef Snape MD, Kelly DF, Lewis S et al (2008) Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336:1487–1491PubMedCrossRef
21.
Zurück zum Zitat Southern J, Crowley-Luke A, Borrow R et al (2006) Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24:215–219PubMedCrossRef Southern J, Crowley-Luke A, Borrow R et al (2006) Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24:215–219PubMedCrossRef
22.
Zurück zum Zitat Thomas HL, Andrews N, Trotter C et al (2008) Meningococcal C booster not recommended by evidence. BMJ 337:a1139PubMedCrossRef Thomas HL, Andrews N, Trotter C et al (2008) Meningococcal C booster not recommended by evidence. BMJ 337:a1139PubMedCrossRef
23.
Zurück zum Zitat Tichmann I, Grunert D, Habash S et al (2006) Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2:249–254PubMed Tichmann I, Grunert D, Habash S et al (2006) Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2:249–254PubMed
24.
Zurück zum Zitat Tichmann I, Preidel H, Grunert D et al (2005) Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23:3272–3279PubMedCrossRef Tichmann I, Preidel H, Grunert D et al (2005) Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23:3272–3279PubMedCrossRef
25.
Zurück zum Zitat Trotter CL, Andrews NJ, Kaczmarski EB et al (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367PubMedCrossRef Trotter CL, Andrews NJ, Kaczmarski EB et al (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367PubMedCrossRef
26.
Zurück zum Zitat Trotter CL, Edmunds WJ, Ramsay ME, Miller E (2006) Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin 2:68–73PubMed Trotter CL, Edmunds WJ, Ramsay ME, Miller E (2006) Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Hum Vaccin 2:68–73PubMed
27.
Zurück zum Zitat Trotter CL, Ramsay ME, Gray S et al (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6:616–618PubMedCrossRef Trotter CL, Ramsay ME, Gray S et al (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6:616–618PubMedCrossRef
28.
Zurück zum Zitat Vazquez L, Garcia F, Ruttimann R et al (2008) Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr 97:1243–1249PubMedCrossRef Vazquez L, Garcia F, Ruttimann R et al (2008) Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr 97:1243–1249PubMedCrossRef
29.
Zurück zum Zitat Vestrheim DF, Lovoll O, Aaberge IS et al (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277–3281PubMedCrossRef Vestrheim DF, Lovoll O, Aaberge IS et al (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277–3281PubMedCrossRef
30.
Zurück zum Zitat Whitney CG, Pilishvili T, Farley MM et al (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502PubMedCrossRef Whitney CG, Pilishvili T, Farley MM et al (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368:1495–1502PubMedCrossRef
Metadaten
Titel
Unterschiedliche Impfschemata in Europa
Führen alle Wege nach Rom?
verfasst von
Univ.-Prof. Dr. U. Wiedermann
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Monatsschrift Kinderheilkunde / Ausgabe 8/2009
Print ISSN: 0026-9298
Elektronische ISSN: 1433-0474
DOI
https://doi.org/10.1007/s00112-009-1974-1

Weitere Artikel der Ausgabe 8/2009

Monatsschrift Kinderheilkunde 8/2009 Zur Ausgabe

In eigener Sache

Galenus-Preis 2009

Einführung zum Thema

Impfungen

Pädiatrie aktuell

Pädiatrie aktuell

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.